NASDAQ:MDLN Medline (MDLN) Stock Price, News & Analysis $37.70 +1.68 (+4.66%) Closing price 04:00 PM EasternExtended Trading$37.30 -0.40 (-1.06%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Medline Stock (NASDAQ:MDLN) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Medline alerts:Sign Up Key Stats Today's Range$36.10▼$37.8150-Day Range$36.02▼$48.2652-Week Range$34.89▼$50.88Volume8.09 million shsAverage Volume6.73 million shsMarket Capitalization$49.53 billionP/E RatioN/ADividend YieldN/APrice Target$50.85Consensus RatingModerate Buy Company Overview Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers. In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations. Its offerings typically include direct delivery, customized kit and procedure-packaging services, inventory management programs and value‑added services such as clinical education and operational consulting. These capabilities are aimed at improving clinical workflow and supporting large, complex supply networks. Medline operates through an extensive distribution network and serves customers across multiple geographies, with a primary focus on North American healthcare markets alongside international sales and distribution activity. The company is run by an executive leadership team responsible for its commercial, operational and clinical service lines. As a company listed on the NASDAQ under the symbol MDLN, Medline positions itself as an integrated supplier and supply‑chain partner for the healthcare industry.AI Generated. May Contain Errors. Read More Medline Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreMDLN MarketRank™: Medline scored higher than 83% of companies evaluated by MarketBeat, and ranked 10th out of 80 stocks in the manufacturing sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.4 / 5Analyst RatingModerate Buy Consensus RatingMedline has received a consensus rating of Moderate Buy. The company's average rating score is 2.83, and is based on 2 strong buy ratings, 21 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialMedline has a consensus price target of $50.85, representing about 34.9% upside from its current price of $37.70.Amount of Analyst CoverageMedline has been the subject of 13 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Medline's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth9.33% Earnings GrowthEarnings for Medline are expected to grow by 9.33% in the coming year, from $1.50 to $1.64 per share.Price to Earnings Growth RatioMedline has a PEG Ratio of 5.20. PEG Ratios above 1 indicate that a company could be overvalued. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.40% of the float of Medline has been sold short.Short Interest Ratio / Days to CoverMedline has a short interest ratio ("days to cover") of 3.72, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Medline has recently decreased by 1.56%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMedline does not currently pay a dividend.Dividend GrowthMedline does not have a long track record of dividend growth. News and Social Media1.7 / 5News Sentiment-0.25 News SentimentMedline has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.59 average news sentiment score of Manufacturing companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Medline this week, compared to 6 articles on an average week.Search InterestOnly 7 people have searched for MDLN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows9 people have added Medline to their MarketBeat watchlist in the last 30 days. This is an increase of 350% compared to the previous 30 days. Company OwnershipN/AInsider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Medline insiders have not sold or bought any company stock.Percentage Held by InstitutionsMedline has minimal institutional ownership at this time.Read more about Medline's insider trading history. Receive MDLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Medline and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MDLN Stock News HeadlinesMedline shares rise as investors refocus on raised 2026 sales outlook after post-earnings selloff3 hours ago | quiverquant.comQMedline deploys new AutoStore installation at distribution center in Aurora, ColoradoMay 18 at 5:42 PM | prnewswire.comYour $29.97 book is free todayWhy Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up. This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account.May 19 at 1:00 AM | Profits Run (Ad)Medline (NASDAQ:MDLN) Given New $40.00 Price Target at BNP Paribas ExaneMay 15, 2026 | americanbankingnews.comMedline Inc.May 13, 2026 | marketwatch.comIs Medline (MDLN) Offering Opportunity After Recent Share Price Pullback And DCF Estimate?May 10, 2026 | finance.yahoo.comMedline (MDLN) Receives a Buy from JefferiesMay 8, 2026 | theglobeandmail.comMedline Reports First Quarter 2026 Results - The Globe and MailMay 7, 2026 | theglobeandmail.comSee More Headlines MDLN Stock Analysis - Frequently Asked Questions How have MDLN shares performed this year? Medline's stock was trading at $42.00 at the beginning of 2026. Since then, MDLN shares have decreased by 10.2% and is now trading at $37.70. How were Medline's earnings last quarter? Medline (NASDAQ:MDLN) issued its quarterly earnings data on Wednesday, May, 6th. The company reported $0.33 earnings per share for the quarter, topping analysts' consensus estimates of $0.29 by $0.04. The firm's quarterly revenue was up 10.7% on a year-over-year basis. Read the conference call transcript. When did Medline IPO? Medline (MDLN) raised $7 billion in an initial public offering on Wednesday, December 17th 2025. The company issued 248,439,654 shares at a price of $26.00-$30.00 per share. When does the company's lock-up period expire? Medline's lock-up period expires on Monday, June 15th. Medline had issued 216,034,482 shares in its public offering on December 17th. The total size of the offering was $6,264,999,978 based on an initial share price of $29.00. After the expiration of the company's lock-up period, restrictions preventing major shareholders and company insiders from selling shares in the company will be lifted. Who are Medline's major shareholders? Top institutional investors of Medline include Janus Henderson Group PLC (0.87%), WCM Investment Management LLC (0.55%), Healthcare of Ontario Pension Plan Trust Fund (0.38%) and Bessemer Group Inc. (0.27%). Insiders that own company stock include Group Vii S1 LLC Tc, Aggregator Lp Mozart II, Cp Circle Ml Holdco Gp, Llc, Carlyle Group Inc, Mozart Coinvestment Ho Carlyle, Tc Group Cayman Investment Hol, Private Ltd Gic, Andrew J Mills, Charles N Mills and Hellman & Friedman Capital Par. View institutional ownership trends. How do I buy shares of Medline? Shares of MDLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings5/06/2026Today5/19/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorManufacturing Industry Surgical, Medical, And Dental Instruments And Supplies Sub-IndustryMedical Equipment Current SymbolNASDAQ:MDLN CIK2046386 WebN/A Phone(847) 949-3000FaxN/AEmployees43,000Year Founded1966Price Target and Rating Average Price Target for Medline$50.85 High Price Target$62.00 Low Price Target$40.00 Potential Upside/Downside+34.9%Consensus RatingModerate Buy Rating Score (0-4)2.83 Research Coverage29 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E Ratio25.13 P/E Growth5.2Net IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual Sales$28.43 billion Price / Sales1.74 Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares1,313,690,000Free FloatN/AMarket Cap$49.53 billion OptionableN/A BetaN/A Social Links Beginner's Guide To Retirement StocksClick the link to see MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:MDLN) was last updated on 5/19/2026 by MarketBeat.com Staff. From Our PartnersSpaceX eyes a 1.75 trillion valuation - here's what to knowElon Musk's team has quietly filed confidential paperwork with the SEC for what Bloomberg estimates could be a...Brownstone Research | SponsoredIran's New Leader Just Said Something That Should Terrify Every AmericanIran's Supreme Leader has declared the Strait of Hormuz closed as leverage against the U.S. - and with 40% of ...American Alternative | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredTrump's gold order: the announcement they won't put on the front pageOn August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredMy feud with Zohran MamdaniEmmy-winning analyst releases his next big story Whitney Tilson shocked the nation on 60 Minutes when he ac...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredWhy this tiny stock may move before the SpaceX IPO dropsThe projected SpaceX and xAI S-1 filing hits the SEC on June 1st - and analyst Dylan Jovine says $1.75 trillio...Behind the Markets | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Medline Please log in to your account or sign up in order to add this asset to your watchlist. Share Medline With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.